RAD001-Adjuvanted Influenza Vaccine Synergizes With Anti–Programmed Cell Death Protein 1 Therapy to Enhance Antitumor Immunity in Programmed Cell Death Ligand 1–Low Murine Lung Cancer
RAD001-adjuvanted influenza vaccination safely enhances the efficacy of anti-PD-1 therapy in PD-L1–low murine lung cancer by promoting a pro-inflammatory immune microenvironment and suggests that strategic vaccine adjuvant selection can broaden the therapeutic reach of immune checkpoint inhibitors.